Carmustine medac (previously Carmustine Obvius) Europos Sąjunga - slovakų - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastické činidlá - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Erleada Europos Sąjunga - slovakų - EMA (European Medicines Agency)

erleada

janssen-cilag international nv - apalutamide - prostatické nádory - endokrinná terapia - erleada je uvedené:v dospelých mužov na liečbu non metastatickým kastrácia rezistentný karcinóm prostaty (nmcrpc), ktorí majú vysoké riziko vzniku metastázy. v dospelých mužov na liečbu metastatickým hormón-citlivé rakovinu prostaty (mhspc) v kombinácii s androgén deprivácie terapia (pdo).